KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Deferred Taxes (2016 - 2026)

Bristol Myers Squibb has reported Deferred Taxes over the past 18 years, most recently at $161.0 million for Q1 2026.

  • Quarterly Deferred Taxes fell 27.8% to $161.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.0 billion through Mar 2026, up 11.08% year-over-year, with the annual reading at -$965.0 million for FY2025, 53.81% up from the prior year.
  • Deferred Taxes was $161.0 million for Q1 2026 at Bristol Myers Squibb, up from -$392.0 million in the prior quarter.
  • Over five years, Deferred Taxes peaked at $223.0 million in Q1 2025 and troughed at -$1.3 billion in Q4 2023.
  • The 5-year median for Deferred Taxes is -$548.0 million (2023), against an average of -$524.6 million.
  • Year-over-year, Deferred Taxes tumbled 1915.62% in 2022 and then surged 131.36% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at -$624.0 million in 2022, then plummeted by 112.66% to -$1.3 billion in 2023, then soared by 40.39% to -$791.0 million in 2024, then surged by 50.44% to -$392.0 million in 2025, then surged by 141.07% to $161.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMY's Deferred Taxes are $161.0 million (Q1 2026), -$392.0 million (Q4 2025), and -$359.0 million (Q3 2025).